American Trial Using Tranexamic Acid in Thrombocytopenia

PHASE3CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

March 31, 2020

Study Completion Date

June 11, 2020

Conditions
Thrombocytopenia
Interventions
DRUG

Tranexamic Acid

Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, TXA 1.0 gram will be administered. When given PO, TXA 1.3 grams will be administered

DRUG

Placebo

Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered

Trial Locations (3)

15213

University of Pittsburgh, Pittsburgh

21599

University of North Carolina, Chapel Hill

98195

University of Washington, Seattle

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Washington

OTHER

NCT02578901 - American Trial Using Tranexamic Acid in Thrombocytopenia | Biotech Hunter | Biotech Hunter